Saturday 17 October 2026
Export KIDS’s income statement to Excel — free account
OrthoPediatrics Corp.
KIDS Healthcare Medical Devices
OrthoPediatrics Corp.’s revenue for fiscal 2025 (year ended December 2025) was $236.3 million, up 15.4% from fiscal 2024. In the quarter to June 2026, revenue grew 15.4%, EPS was flat, free cash flow grew 77.6% and total debt was flat, each against the same quarter a year earlier. Revenue growth for five consecutive years.
21.95
0.62
−2.75%
Follow KIDS
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
1.82 | 1.54 | 1.76 | 1.92 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
495.75 | (114.35) | 40.26 | (751.60) | |
P/B ratio |
1.34 | 1.11 | 1.20 | 1.25 | |
Price to Tangible BV |
3.10 | 2.56 | 2.61 | 2.62 | |
EV/Sales |
2.02 | 1.74 | 1.91 | 2.08 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
68.81 | (106.07) | (92.94) | (24.69) | |
EV/FCF |
(129.34) | (28.67) | (24.95) | (15.02) | |
Quick Ratio |
2.06 | 2.23 | 2.53 | 3.34 | |
Current Ratio |
4.78 | 5.21 | 5.55 | 7.40 | |
Net Debt/EBITDA |
30.33 | (17.79) | (154.81) | 1,091.12 | |
Debt/Assets |
19.09% | 19.39% | 19.10% | 19.63% | |
Debt/Equity |
0.28 | 0.29 | 0.28 | 0.28 | |
Asset Turnover |
0.50 | 0.50 | 0.48 | 0.46 | |
Operating CF/Net income |
(0.13) | 0.31 | (1.02) | 0.05 | |
Capex/Depreciation |
(0.71) | (0.31) | (0.08) | (0.30) | |
Interest Coverage |
(1.61) | (3.97) | (4.23) | (5.17) | |
Research and Development Expense of Revenue |
3.30% | 3.76% | 3.67% | 3.81% | |
Selling, General and Administrative Expense of Revenue |
76.74% | 83.38% | 78.49% | 78.05% | |
Intangible Assets out of Total Assets |
0.38 | 0.38 | 0.37 | 0.37 | |
Share Based Compensation of Revenue |
5.94% | 6.71% | 7.17% | 6.94% | |
Graham Net Nets |
0.18 | 0.22 | 0.23 | 0.23 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(8.78%) | (10.59%) | (9.52%) | (10.52%) | |
Free Cash Flow Yield |
(0.86%) | (3.92%) | (4.34%) | (7.22%) | |
Revenue per Share |
2.93 | 2.51 | 2.63 | 2.60 | |
Operating CF per Share |
0.04 | (0.14) | 0.44 | (0.02) | |
Capex per Share |
(0.17) | (0.07) | (0.03) | (0.12) | |
Free Cash Flow per Share |
(0.13) | (0.21) | 0.42 | (0.15) | |
Cash per Share |
1.99 | 2.15 | 2.68 | 2.54 | |
Shareholders Equity per Share |
14.29 | 14.30 | 14.77 | 14.82 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
14.29 | 14.30 | 14.77 | 14.82 | |
Free Cash Flow |
(3.12) | (5.05) | 9.75 | (3.42) | |
Working Capital |
199.66 | 198.68 | 210.22 | 212.62 | |
Capital Expenditures |
(4.04) | (1.76) | (0.60) | (2.84) | |
Net Current Asset Value |
84.73 | 82.39 | 94.39 | 101.68 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.06 | 0.03 | 0.01 | 0.05 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
57.37 | 49.21 | 48.10 | 47.05 | |
Average Payables |
17.46 | 16.95 | 13.85 | 9.41 | |
Average Inventory |
131.42 | 126.89 | 125.40 | 124.87 | |
Average Assets |
507.50 | 486.22 | 490.92 | 491.39 | |
Average Common Equity |
349.56 | 342.93 | 350.58 | 360.11 |
Columns are period end dates